Shuangshuang Fang, Zhenyu Liu, Qi Qiu, Zhenchao Tang, Yang Yang, Zhongsheng Kuang, Xiaohua Du, Shanshan Xiao, Yanyan Liu, Yuanbin Luo, Liping Gu, Li Tian, Xiaoxia Liang, Guiling Fan, Yu Zhang, Ping Zhang, Weixun Zhou, Xiuli Liu, Jie Tian, Wei Wei
OBJECTIVE: Patients with gastric atrophy and intestinal metaplasia (IM) were at risk for gastric cancer, necessitating an accurate risk assessment. We aimed to establish and validate a diagnostic approach for gastric biopsy specimens using deep learning and OLGA/OLGIM for individual gastric cancer risk classification. METHODS: In this study, we prospectively enrolled 545 patients suspected of atrophic gastritis during endoscopy from 13 tertiary hospitals between December 22, 2017, to September 25, 2020, with a total of 2725 whole-slide images (WSIs)...
March 2024: Gastric Cancer
Ryota Matsui, Satoshi Ida, Motonari Ri, Rie Makuuchi, Masaru Hayami, Koshi Kumagai, Manabu Ohashi, Takeshi Sano, Souya Nunobe
BACKGROUND: The relationship between preoperative prealbumin levels and long-term prognoses in patients with gastric cancer after gastrectomy has not been fully investigated. This study clarified the effect of preoperative prealbumin levels on the long-term prognosis of patients with gastric cancer after gastrectomy. METHODS: This retrospective cohort study included consecutive patients who underwent radical gastrectomy for primary pStage I-III gastric cancer and whose preoperative prealbumin levels were measured between May 2006 and March 2017...
February 24, 2024: Gastric Cancer
Jiankun Liu, Tienian Zhu, Ruijing Zhao, Wenjun Ren, Fei Zhao, Jingpu Liu
BACKGROUND: HER2-targeted therapies have improved the outcomes of HER2-positive gastric cancer (GC), yet resistance remains a challenge. We sought to explore the effects of reversible and irreversible HER2 tyrosine kinase inhibitors (TKIs) alone or in combination with the HER2-targeting antibody drug conjugate trastuzumab deruxtecan (T-Dxd). METHODS: The effects of HER2-TKIs on HER2 and downstream signaling were evaluated via Western blotting. Proteasomal inhibitors and co-immunoprecipitation assays were performed to explore the role of proteasomal degradation in HER2 expression modulation, and immunofluorescence assays were employed to explore mechanisms of HER2 internalization...
February 22, 2024: Gastric Cancer
Yuki Ito, Mitsuro Kanda, Masahiro Sasahara, Chie Tanaka, Dai Shimizu, Shinichi Umeda, Yoshikuni Inokawa, Norifumi Hattori, Masamichi Hayashi, Goro Nakayama, Yasuhiro Kodera
BACKGROUND: Advanced gastric cancer (GC) has a poor prognosis. This study aimed to identify novel GC-related genes as potential therapeutic targets. METHODS: Killer cell lectin-like receptor G2 (KLRG2) was identified as a candidate gene by transcriptome analysis of metastatic GC tissues. Small interfering RNA-mediated KLRG2 knockdown in human GC cell lines was used to investigate KLRG2 involvement in signaling pathways and functional behaviors in vitro and in vivo...
February 22, 2024: Gastric Cancer
(no author information available yet)
No abstract text is available yet for this article.
February 14, 2024: Gastric Cancer
Xiulin Zhang, Yang He, Xiaolu Zhang, Bo Fu, Zidai Song, Liang Wang, Rui Fu, Xuancheng Lu, Jin Xing, Jianyi Lv, Meng Guo, Xueyun Huo, Xin Liu, Jing Lu, Xiaoyan Du, Zhongming Ge, Zhenwen Chen, Changlong Li
Helicobacter pylori (H. pylori, Hp) has been designated a class I carcinogen and is closely associated with severe gastric diseases. During colonization in the gastric mucosa, H. pylori develops immune escape by inducing host immune tolerance. The gastric epithelium acts as the first line of defense against H. pylori, with Toll-like receptors (TLRs) in gastric epithelial cells being sensitive to H. pylori components and subsequently activating the innate immune system. However, the mechanism of immune tolerance induced by H...
February 4, 2024: Gastric Cancer
Zev A Wainberg, Yoon-Koo Kang, Keun-Wook Lee, Shukui Qin, Kensei Yamaguchi, In-Ho Kim, Anwaar Saeed, Sang Cheul Oh, Jin Li, Haci Mehmet Turk, Alexandra Teixeira, Erika Hitre, Adrian A Udrea, Giovanni Gerardo Cardellino, Raquel Guardeño Sanchez, Anita Zahlten-Kümeli, Kate Taylor, Peter C Enzinger
BACKGROUND: We report the final results of the randomized phase 2 FIGHT trial that evaluated bemarituzumab, a humanized monoclonal antibody selective for fibroblast growth factor receptor 2b (FGFR2b), plus mFOLFOX6 in patients with FGFR2b-positive (2 + /3 + membranous staining by immunohistochemistry), HER-2-negative gastric or gastroesophageal junction cancer (GC). METHODS: Patients received bemarituzumab (15 mg/kg) or placebo once every 2 weeks with an additional bemarituzumab (7...
February 3, 2024: Gastric Cancer
Anissa Zaafour, Lornella Seeneevassen, Tra Ly Nguyen, Coralie Genevois, Nour Nicolas, Elodie Sifré, Alban Giese, Chloé Porcheron, Jean Descarpentrie, Pierre Dubus, Abdel-Majid Khatib, Christine Varon
BACKGROUND: Gastric cancer (GC), the fourth leading cause of cancer-related death worldwide, with most deaths caused by advanced and metastatic disease, has limited curative options. Here, we revealed the importance of proprotein convertases (PCs) in the malignant and metastatic potential of GC cells through the regulation of the YAP/TAZ/TEAD pathway and epithelial-to-mesenchymal transition (EMT) in cancer stem cells (CSC). METHODS: The general PCs inhibitor, decanoyl-RVKR-chloromethyl-ketone (CMK), was used to repress PCs activity in CSCs of various GC cell lines...
January 27, 2024: Gastric Cancer
Ben Yue, Jianjun Chen, Tianshang Bao, Yuanruohan Zhang, Linxi Yang, Zizhen Zhang, Zheng Wang, Chunchao Zhu
BACKGROUND: Chromosome gains or localized amplifications are frequently observed in human gastric cancer (GC) and are major causes of aberrant oncogene activation. However, the significance of long non-coding RNAs (LncRNAs) in the above process is largely unknown. METHODS: The copy number aberrations (CNAs) data of GC samples were downloaded and analyzed from the TCGA database. qRT-PCR and fluorescence in situ hybridization were used to evaluate the expression of Linc01711 in GC...
January 25, 2024: Gastric Cancer
Elisabetta Puliga, Chiara De Bellis, Sandra Vietti Michelina, Tania Capeloa, Cristina Migliore, Claudia Orrù, Gian Luca Baiocchi, Giovanni De Manzoni, Filippo Pietrantonio, Rossella Reddavid, Uberto Fumagalli Romario, Chiara Ambrogio, Simona Corso, Silvia Giordano
BACKGROUND: Gastric cancer (GC) is the third leading cause of cancer-related death worldwide, with a poor prognosis for patients with advanced disease. Since the oncogenic role of KRAS mutants has been poorly investigated in GC, this study aims to biochemically and biologically characterize different KRAS-mutated models and unravel differences among KRAS mutants in response to therapy. METHODS: Taking advantage of a proprietary, molecularly annotated platform of more than 200 GC PDXs (patient-derived xenografts), we identified KRAS-mutated PDXs, from which primary cell lines were established...
January 23, 2024: Gastric Cancer
Peng Xu, Kanghui Liu, Shansong Huang, Jialun Lv, Zhengyuan Yan, Han Ge, Quan Cheng, Zetian Chen, Peicheng Ji, Yawei Qian, Bowen Li, Hao Xu, Li Yang, Zekuan Xu, Diancai Zhang
BACKGROUND: Peritoneal metastasis (PM), one of the most typical forms of metastasis in advanced gastric cancer (GC), indicates a poor prognosis. Exploring the potential molecular mechanism of PM is urgently necessary, as it has not been well studied. E3 ubiquitin ligase has been widely established to exert a biological function in various cancers, but its mechanism of action in GC with PM remains unknown. METHODS: The effect of MIB1 on PM of GC was confirmed in vitro and in vivo...
January 22, 2024: Gastric Cancer
Masanori Tokunaga, Nozomu Machida, Junki Mizusawa, Seiji Ito, Hiroshi Yabusaki, Motohiro Hirao, Masaya Watanabe, Hiroshi Imamura, Takahiro Kinoshita, Takushi Yasuda, Jun Hihara, Haruhiko Fukuda, Takaki Yoshikawa, Narikazu Boku, Masanori Terashima
BACKGROUND: This randomized phase II study explored the superiority of trastuzumab plus S-1 plus cisplatin (SP) over SP alone as neoadjuvant chemotherapy (NAC) for HER2-positive resectable gastric cancer with extensive lymph node metastasis. METHODS: Eligible patients with HER2-positive gastric or esophagogastric junction cancer and extensive lymph node metastasis were randomized to receive three or four courses of preoperative chemotherapy with SP (arm A) or SP plus trastuzumab (arm B)...
January 19, 2024: Gastric Cancer
Sho Suzuki, Yusuke Monno, Ryo Arai, Masaki Miyaoka, Yosuke Toya, Mitsuru Esaki, Takuya Wada, Waku Hatta, Ayaka Takasu, Shigeaki Nagao, Fumiaki Ishibashi, Yohei Minato, Kenichi Konda, Takahiro Dohmen, Kenji Miki, Masatoshi Okutomi
BACKGROUNDS: Cycle-consistent generative adversarial network (CycleGAN) is a deep neural network model that performs image-to-image translations. We generated virtual indigo carmine (IC) chromoendoscopy images of gastric neoplasms using CycleGAN and compared their diagnostic performance with that of white light endoscopy (WLE). METHODS: WLE and IC images of 176 patients with gastric neoplasms who underwent endoscopic resection were obtained. We used 1,633 images (911 WLE and 722 IC) of 146 cases in the training dataset to develop virtual IC images using CycleGAN...
January 19, 2024: Gastric Cancer
Bogun Jang, Su-Hyung Lee, Iryna Dovirak, Hyesung Kim, Supriya Srivastava, Ming Teh, Khay-Guan Yeoh, Jimmy B So, Stephen K K Tsao, Christopher J Khor, Tiing Leong Ang, James R Goldenring
BACKGROUND: Mucosal gastric atrophy and intestinal metaplasia (IM) increase the risk for the development of gastric cancer (GC) as they represent a field for development of dysplasia and intestinal-type gastric adenocarcinoma. METHODS: We have investigated the expression of two dysplasia markers, CEACAM5 and TROP2, in human antral IM and gastric tumors to assess their potential as molecular markers. RESULTS: In the normal antral mucosa, weak CEACAM5 and TROP2 expression was only observed in the foveolar epithelium, while inflamed antrum exhibited increased expression of both markers...
January 14, 2024: Gastric Cancer
Chikanori Tsutsumi, Kenoki Ohuchida, Naoki Katayama, Yutaka Yamada, Shoichi Nakamura, Sho Okuda, Yoshiki Otsubo, Chika Iwamoto, Nobuhiro Torata, Kohei Horioka, Koji Shindo, Yusuke Mizuuchi, Naoki Ikenaga, Kohei Nakata, Eishi Nagai, Takashi Morisaki, Yoshinao Oda, Masafumi Nakamura
BACKGROUND: Gastric cancer (GC) is characterized by an immunosuppressive and treatment-resistant tumor immune microenvironment (TIME). Here, we investigated the roles of different immunosuppressive cell types in the development of the GC TIME. METHODS: Single-cell RNA sequencing (scRNA-seq) and multiplex immunostaining of samples from untreated or immune checkpoint inhibitor (ICI)-resistant GC patients were used to examine the correlation between certain immunosuppressive cells and the prognosis of GC patients...
January 13, 2024: Gastric Cancer
Ji-Hyun Kim, Nayoung Kim, Du Hyun Song, Yonghoon Choi, Eun-Bi Jeon, Sihyun Kim, Yu Kyung Jun, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Dong Ho Lee, Hyeon Jeong Oh, Hye Seung Lee, Young Suk Park, Sang-Hoon Ahn, Yun-Suhk Suh, Do Joong Park, Hyung Ho Kim, Ji-Won Kim, Jin Won Kim, Keun-Wook Lee, Won Chang, Ji Hoon Park, Yoon Jin Lee, Kyoung Ho Lee, Young Hoon Kim, Soyeon Ahn
BACKGROUND: Epstein-Barr virus (EBV)-associated gastric cancer (EBVaGC) has been reported to account for approximately 5-16% of all GCs with good prognosis compared to EBV-negative GC. We evaluated the clinicopathological characteristics of EBVaGC including survival rate in South Korea. METHODS: A total of 4,587 patients with GC who underwent EBV in situ hybridization (EBV-ISH) were prospectively enrolled at the Seoul National University Bundang Hospital from 2003 to 2021...
January 11, 2024: Gastric Cancer
Takuji Gotoda, Hideki Ishikawa, Chika Kusano, Sho Suzuki, Hirohide Ohnishi, Kentaro Sugano, Yutaka Matsuyama
BACKGROUND: Although the risk of gastric cancer can be stratified according to Helicobacter pylori (H. pylori) IgG antibody titer and pepsinogen levels (ABC classification), a population-based gastric cancer screening system combining serological tests and endoscopy has not been introduced. This study aimed to compare the total testing cost per participant between the ABC classification method and the existing protocol. METHODS: Using the minimization method with sex and age as allocation factors, 1206 participants were randomly assigned to the following two methods for a 5-year intervention: barium photofluorography as primary examination followed by detailed examination with upper gastrointestinal endoscopy (Ba-Endo) and risk-based upper gastrointestinal endoscopy by ABC classification (ABC-Endo)...
January 2024: Gastric Cancer
Eo Jin Kim, Heejung Chae, Young-Soo Park, Min-Hee Ryu, Hyung-Don Kim, Junyoung Shin, Yang Soon Park, Mee Sun Moon, Yoon-Koo Kang
BACKGROUND: Epstein-Barr virus-associated gastric cancer (EBVaGC) is a distinct molecular subgroup showing excellent outcomes after surgery for localized disease. Prominent immune cell infiltration in EBVaGC reflects the immunogenicity of Epstein-Barr virus (EBV) and, as suggested by some investigators, responsiveness to immune checkpoint inhibitors in the palliative setting. However, few data are available on the prevalence, clinical characteristics, and prognosis of EBVaGC patients receiving palliative cytotoxic chemotherapy...
January 2024: Gastric Cancer
Takaki Yoshikawa, Masanori Terashima, Junki Mizusawa, Souya Nunobe, Yasunori Nishida, Takanobu Yamada, Masahide Kaji, Takashi Nomura, Shinji Hato, Yasuhiro Choda, Hiroshi Yabusaki, Kazuhiro Yoshida, Kazunari Misawa, Toru Masuzawa, Masahiro Tsuda, Yasuyuki Kawachi, Hiroshi Katayama, Haruhiko Fukuda, Yukinori Kurokawa, Narikazu Boku, Takeshi Sano, Mitsuru Sasako
BACKGROUND: Postoperative adjuvant chemotherapy with S-1 for 1 year (corresponding to eight courses) is the standard treatment for pathological stage II gastric cancer. The phase III trial (JCOG1104) investigating the non-inferiority of four courses of S-1 to eight courses was terminated due to futility at the first interim analysis. To confirm the primary results, we reported the results after a 5-years follow-up in JCOG1104. METHODS: Patients histologically diagnosed with stage II gastric cancer after radical gastrectomy were randomly assigned to receive S-1 for eight or four courses...
January 2024: Gastric Cancer
I A Caspers, H D Biesma, K Wiklund, F Pontén, P Lind, M Nordsmark, K Sikorska, E Meershoek-KleinKranenbarg, H H Hartgrink, C J H van de Velde, J W van Sandick, M Verheij, A Cats, N C T van Grieken
BACKGROUND: In the era of individualized gastric cancer (GC) treatment, accurate determination of histological subtype becomes increasingly relevant. As yet, it is unclear whether preoperative chemotherapy may affect the histological subtype. The aim of this study was to assess concordance in histological subtype between pretreatment biopsies and surgical resection specimens before and after the introduction of perioperative treatment. METHODS: Histological subtype was centrally determined in paired GC biopsies and surgical resection specimens of patients treated with either surgery alone (SA) in the Dutch D1/D2 study or with preoperative chemotherapy (CT) in the CRITICS trial...
January 2024: Gastric Cancer
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.